RT Journal Article
SR Electronic
T1 The premature mortality to incidence ratio (PREMIER): a person-centred measure of cancer burden
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.10.17.21265122
DO 10.1101/2021.10.17.21265122
A1 Banham, David
A1 Karnon, Jonathan
A1 Brown, Alex
A1 Roder, David
A1 Lynch, John
YR 2021
UL http://medrxiv.org/content/early/2021/10/18/2021.10.17.21265122.abstract
AB Background Cancer control initiatives are informed by quantifying the capacity to reduce cancer burden through effective interventions. Burden measures using health administrative data are a sustainable way to support monitoring and evaluating of outcomes among patients and populations. The PREmature Mortality to IncidencE Ratio (PREMIER) is one such burden measure. We use data on Aboriginal and non-Aboriginal South Australians from 1990 to 2010 to show how PREMIER quantifies disparities in cancer burden: between populations; between sub-population cohorts where stage at diagnosis is available; and when follow-up is constrained to 24-months after diagnosis.Method PREMIERcancer is the ratio of years of life expectancy lost due to cancer (YLLcancer) to life expectancy years at risk at time of cancer diagnosis (LYAR) for each person. The Global Burden of Disease standard life table provides referent life expectancies. PREMIERcancer was estimated for the population of cancer cases diagnosed in South Australia from 1990 to 2010. Cancer stage at diagnosis was also available for cancers diagnosed in Aboriginal people and a cohort of non-Aboriginal people matched by sex, year of birth, primary cancer site and year of diagnosis.Results Cancers diagnoses (N=144,891) included 777 among Aboriginal people. Cancer burden described by PREMIERcancer was higher among Aboriginal than non-Aboriginal (0.55, 95%CIs 0.52-0.59 versus 0.39, 95%CIs 0.39-0.40). Diagnoses at younger ages among Aboriginal people, 7 year higher LYAR (31.0, 95%CIs 30.0-32.0 versus 24.1, 95%CIs 24.1-24.2) and higher premature cancer mortality (YLLcancer=16.3, 95%CIs 15.1-17.5 versus YLLcancer=8.2, 95%CIs 8.2-8.3) influenced this. Disparities in cancer burden between the matched Aboriginal and non-Aboriginal cohorts manifested 24-months after diagnosis with PREMIERcancer 0.44, 95%CIs 0.40-0.47 and 0.28, 95%CIs 0.25-0.31 respectively.Conclusion PREMIER described disproportionately higher cancer burden among Aboriginal people in comparisons involving: all people diagnosed with cancer; the matched cohorts; and, within groups diagnosed with same staged disease. The extent of disparities were evident 24-months after diagnosis. This is evidence of Aboriginal peoples’ substantial capacity to benefit from cancer control initiatives, particularly those leading to earlier detection and treatment of cancers. PREMIER’s use of readily available, person-level administrative records can help evaluate health care initiatives addressing this need.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe CanDAD project was funded by National Health and Medical Research Council (APP1072243), Cancer Council SAs Beat Cancer Project with project partners in-kind support. DB is supported in part by an Australian Government Research Training Program Scholarship. AB is supported by the Sylvia and Charles Viertel Senior Medical Research Fellowship. The funders were not involved in the analysis, data interpretation and writing of this manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The South Australian Aboriginal Health Research Ethics Committee (AHREC 04-12-461) and SA Health Human Research Ethics Committee (SA Health HREC HREC/12/SAH/35) approved the use of population cancer registry records. CanDADs Aboriginal Community Reference Group governance ensured alignment of the study protocol with South Australian Aboriginal Health Research Accord principles.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe datasets generated and/or analysed during the current study are not publicly available due to privacy reasons, including the provisions of the Australian Privacy Principles. The study's data comprised of de-identified unit record administrative records and were used under privileged arrangements set out in a study specific confidentiality deed. The data cannot be accessed by another party without relevant data custodian and human research ethics approvals.95% CIs95% confidence intervalsCanDADCancer Data and Aboriginal DisparitiesLYARLife Years at RiskPREMIERPREmature Mortality to IncidencE Ratio calculated as YLL/LYAR for each casePREMIERcancerPREmature Mortality to IncidencE Ratio calculated as YLLcancer/LYAR for each casePREMIERcancer 24-monthsPREmature Mortality to IncidencE Ratio up to 24-months after diagnosis calculated as YLLcancer 24-months/LYAR for each casePROMsPatient Reported Outcome MeasuresYLLYears of Life LostYLLcancerYears of Life Lost associated with cancer deathYLLcancer 24-monthsYears of Life Lost associated with cancer death up to 24-months after diagnosisSACRSouth Australian Cancer Registry